Skip to main content
TipRanks
Go Ultimate75% OFF

Omada Health, Inc. (OMDA) Q3 2026 Earnings Report

197 Followers

OMDA Q3 2026 EPS Results

Actual EPS
$0.20
Consensus EPS
$0.10
Beat/Miss
Beat by +$0.10
One Year Ago EPS
-$0.06

OMDA Q3 2026 Revenue Results

Actual Revenue
$91.31M
Expected Revenue
$85.65M
Beat/Miss
Beat by +$5.66M
YoY Revenue Growth
+34.21%

Earnings Announcement Details

Quarter
Q3 2026
Date
11/05/2026
Time
After Close
Conference Call
Thursday, November 5, 2026
OMDA Upcoming Earnings

Omada Health, Inc.'s next earnings date is estimated for March 11, 2027, based on past reporting schedules.

Q3 2026 Earnings Call Audio

OMDA Q3 2026 Earnings Call
0:00 / 0:00

Q3 2026 Earnings Slide Deck

Q3 2026 Earnings Call Summary

Q3 2026
Earnings Call Date:Nov 05, 2026|% Change Since:-24.38%|
Earnings Call Sentiment|Positive

The call was strongly positive. Omada reported record revenue, gross margin, net income, adjusted EBITDA, member tenure, and cash generation, while raising full-year revenue and adjusted EBITDA guidance. Growth was supported by diabetes and hypertension programs, improved enrollment conversion, broader distribution, longer member engagement, and lower cost to serve. The main challenges were normal Q4 seasonal moderation, uncertainty around employer GLP-1 coverage and the timing of the extended selling season, rising healthcare costs, and expected near-term investment-related moderation in adjusted EBITDA.

Company Guidance

Omada raised full year 2026 revenue guidance to $344 million to $346 million, up from $334 million to $340 million, and full year adjusted EBITDA guidance to $32 million to $34 million, up from $21 million to $27 million; at the midpoint, revenue represents approximately 33% growth compared with 2025, while adjusted EBITDA represents an improvement of approximately $27 million compared with 2025 or roughly 5.5x 2025 adjusted EBITDA. Q4 revenue is expected to be below Q3, with new enrollments expected to moderate sequentially and revenue coming primarily from continued engagement among existing members; Q4 adjusted EBITDA is expected to moderate from Q3 as the company adds R&D headcount and ramps care team staffing for the 2027 benefit launch. For 2027, management cited a 20%+-plus growth target, expects the additional estimated 1.5 million covered lives from HCSC to launch on January 1 and phase throughout the entire year, and continues to target 80% longer-term gross margin.

  • Record Q3 Revenue and ProfitabilityQ3 revenue reached $91 million, up 34% year-over-year and approximately 4% sequentially from $88 million in Q2. Omada reported its highest quarterly revenue, highest gross margin, and most profitable quarter to date, with GAAP net income of nearly $7 million versus a GAAP net loss of approximately $3 million a year ago, and adjusted EBITDA of $12 million, up approximately $10 million year-over-year.
  • Gross Margin ExpansionGAAP gross margin was 76%, up from 66% in Q3 of the prior year, while non-GAAP gross margin was 78%, up from 68%. The improvement reflected lower care team delivery costs, maturation of longer-tenured cohorts, and seasonal cost benefits.
  • Raised Full-Year 2026 GuidanceOmada raised full-year 2026 revenue guidance to $344 million-$346 million from $334 million-$340 million previously. At the midpoint, this represents approximately 33% revenue growth compared with 2025. Adjusted EBITDA guidance increased to $32 million-$34 million from $21 million-$27 million previously; the midpoint represents an improvement of approximately $27 million compared with 2025, or roughly 5.5x 2025 adjusted EBITDA.
  • Record Member Base and Continued DemandOmada ended Q3 with approximately 1.13 million total members, up 36% year-over-year, after adding approximately 43,000 net-new members during the quarter. Management attributed the growth to continued demand for its cardiometabolic platform.
  • Diabetes and Hypertension Programs Led GrowthThe diabetes and hypertension programs led year-over-year growth. Strong enrollments early in the quarter, a mix shift toward higher-valued programs, and increased engagement across the member base helped revenue exceed expectations.
  • Higher Revenue per MemberTrailing 12-month revenue per total member was $294 in Q3, compared with $280 in Q3 of the prior year and $284 in Q2. The increase reflected a shift toward higher-priced diabetes and hypertension programs, partially offset by lower billing frequency among longer-tenured members.
  • Improved Retention and Longer Member TenureMember retention improved to 58% from 43% in Q4 2024. Average program tenure reached a record roughly 2 years and 4 months, up 10% year-over-year, more than 30% compared with three years ago, and approximately 2.5 months higher than a year ago.
  • Lower Cost to Serve and Operating LeverageNon-GAAP cost of revenue per total member on a trailing 12-month basis reached an all-time low of $81 in Q3, down from $85 in Q2 and $94 in Q3 2025. Non-GAAP operating expenses were 64% of revenue versus 65% a year ago, reflecting channel-partnership scale, greater productivity from the existing Salesforce, spending discipline, and AI.
  • Strong Balance Sheet and No DebtOmada reported two consecutive profitable quarters, approximately $243 million in cash and cash equivalents at the end of Q3, and no debt. Management said the balance sheet provides flexibility to deploy capital and plans to continue investing in the care model, technology, and commercial reach.
  • HCSC Expansion Adds Covered LivesOmada extended its prevention and hypertension programs with HCSC into the fully insured book in three additional states. The arrangement is expected to potentially reach an additional estimated 1.5 million covered lives at launch in 2027, with the programs embedded at the benefit level so clinically eligible members can enroll directly without a downstream employer sales cycle. The rollout will be phased throughout 2027.
  • Broad PBM and Channel DistributionOmada has commercial relationships with the three largest PBMs, which together processed an estimated 80% of prescription claims in 2025. Its prescribing program is currently in market with Optum, giving the company what management described as the broadest distribution in its history.
  • Strong Multi-Condition Sales ExecutionApproximately 40%-50% of new deals closed in Q3 involved multi-condition or multi-product purchases. Management said the strategy is intended to provide a more seamless care experience for clients whose members often have two or more cardiometabolic conditions.
  • Clinical Evidence Supporting GLP-1 CarePeer-reviewed research found that members in Omada's GLP-1 care track lost nearly twice as much weight as GLP-1 users in non-Omada care at 12 weeks: 6% average weight loss versus 3.3%, with about twice the reduction in body fat and greater preservation of muscle mass on average.
  • Expanded Product and Care CapabilitiesQ3 launches and enhancements included improved onboarding, personalized reminders and recommendations, strengthened nutrition support combining human and AI feedback, cholesterol management, GLP-1 prescribing, and FlexCare. Management also said it is continuing to invest in MSK integration, women's health and menopause learning tracks, and the broader cardiometabolic platform.
  • Enrollment Conversion ImprovementsOmada shifted from enrolling members in weekly groups to enrolling them as they sign up, which increased immediate conversion and contributed partially to the Q3 revenue outperformance. Year-to-date enrollment or yield rate grew approximately 10% compared with the prior year. The company also conducted dozens of tests across email, direct mail, social, and other channels.
  • Care Team Efficiency and AI AdoptionManagement said care delivery achieved significant year-over-year efficiency through standardized work and increased use of AI. Net care-team headcount decreased year-over-year, while AI enabled care teams to support more members and provide more personalized care.
  • Leadership Transition with Continued Strategic InvolvementEffective January 1, 2027, Wei-Li Shao will become CEO and Sean Duffy will become executive chair. Duffy said he intends to remain closely involved in the company's long-term mission, key partnerships, and strategic initiatives.

OMDA Earnings History

OMDA earnings history
Report DateFiscal QuarterForecast / EPSLast Year's EPSEPS YoY ChangePress Release
Mar 11, 20272026 (Q4)0.12-0.08――
Nov 05, 20262026 (Q3)0.100.20-0.06433.33% (+0.26)
Aug 06, 20262026 (Q2)0.060.18-0.24175.00% (+0.42)
May 07, 20262026 (Q1)-0.130.04-0.13130.77% (+0.17)
Mar 05, 20262025 (Q4)0.010.08-0.15154.05% (+0.23)
Nov 06, 20252025 (Q3)-0.08-0.06-0.1763.86% (+0.11)
Aug 07, 20252025 (Q2)-0.12-0.24-0.19-25.00% (-0.05)

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat Missed